Primary Sarcoma of the Pancreas: An Unusual Indication for Pancreaticoduodenectomy
Publication date: Available online 10 October 2018Source: Cirugía Española (English Edition)Author(s): César Muñoz Castro, Guillermo Sepulveda Diaz, Andrea San Pedro Sánchez, Juan Pablo Lahsen Humeres
This article is protected by copyright. All rights reserved.
Soft-tissue sarcomas are a heterogeneous class of tumors that exhibit varying degrees of cellularity and cystic degeneration in response to neoadjuvant chemotherapy. This creates unique challenges in the radiographic assessment of treatment response when relying on conventional markers such as tumor diameter (RECIST criteria). In this case series, we provide a narrative discussion of technique development for whole tumor volume quantitative magnetic resonance imaging (q-MRI), highlighting cases from a small pilot study of 8 patients (9 tumors) pre- and post-neoadjuvant chemotherapy.
ConclusionGefitinib demonstrated modest anti-tumor activity and a manageable safety profile in chemotherapy-refractory solid tumors with EGFR amplification or sensitivity to an EGFR inhibitor identified through a drug-screening platform with PDCs.ClinicalTrials.gov identifierNCT02447419.
Conditions: Ectomesenchymoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medull oblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectode...
Publication date: Available online 24 February 2020Source: European Journal of Surgical OncologyAuthor(s): Kyoungmin Lee, Joon Seon Song, Jeong Eun Kim, Wanlim Kim, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Jong-Seok Lee, Jin-Hee Ahn
British Journal of Cancer, Published online: 26 February 2020; doi:10.1038/s41416-020-0760-7Case–control study of paternal occupational exposures and childhood bone tumours and soft-tissue sarcomas in Great Britain, 1962–2010
In this study, we characterized the antigenic targets of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our study revealed that plasma from a majority of KSHV neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic KSHV-infected ind...
Publication date: March–April 2020Source: The Journal of Foot and Ankle Surgery, Volume 59, Issue 2Author(s): Tommy Tally, Robin Dretler, Tom Cain, Kelly Brennan
Conclusion: Despite promising preclinical rationale and tolerability of the combination therapy, no responses were observed, and the study did not meet parameters for further evaluation in MPNSTs. This trial was registered with (NCT02008877). PMID: 32089640 [PubMed]
Conclusion Both apatinib and anlotinib were effective for the treatment of sarcomas. However, the effectiveness of the two drugs and associated AEs varied based on the histological type of sarcoma. These differences may be due to their different sensitivities to targets such as RET, warranting further study.